Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation

Journal of the American Society of Nephrology

Volumn 9, Issue 9, 1998, Pages 1697-1708

  Jassal, Sarbjit Vanita ^a,d   Roscoe, Janet Mary ^a   Zaltzman, Jeffrey Steven ^a   Mazzulli, Tony ^b   Krajden, Mel ^c   Gadawski, Maryann ^c   Cattran, Daniel Cheyne ^c   Cardella, Carl Joseph ^c   Albert, Shelley Elizabeth ^c   Cole, Edward Herman ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; FAMCICLOVIR; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; SERODIAGNOSIS; VIREMIA;

EID: 0031752217     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Evidence-Based Medicine Working Group: Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA 268: 2420-2425, 1992
2. Mullan F, Jacoby I: The town meeting for technology: The maturation of consensus conferences. JAMA 254: 1068-1072, 1985
3. Canada Communications Group: Canadian Guide to Clinical Preventative Health Care, Quebec, Hull, 1994
4. Sackett DL, Haynes RB, Guyatt GH, Tugwell P: Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd Ed., Boston, Little, Brown and Company, 1991, pp 187-248
5. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733, 1988
6. Woolf SH: Practice guidelines: A new reality in medicine. I. Recent developments. Arch Intern Med 150: 1811-1818, 1990
7. Canadian Task Force on the Periodic Health Examination: The periodic health examination. Can Med Assoc J 121: 1193-1254, 1979
8. Ho M: Epidemiology of cytomegalovirus infections. Rev Infect Dis 12: S701-S710, 1990
9. Snydman DR, Rubin RH, Werner BG: New developments in cytomegalovirus prevention and management. Am J Kidney Dis 21: 217-228, 1993
10. McCarthy JM, Karim MA, Krueger H, Keown PA: The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 55: 1277-1282, 1993
11. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM: Incidence if cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 43: 187-193, 1987
12. The Tricontinental Mycophenylate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenylate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
13. Hirata M, Terasaki PI, Cho YW: Cytomegalovirus antibody status and renal transplantation: 1987-1994. Transplantation 62: 34-37, 1996
14. Basadonna G, Feria A, Perez R, Klein H, Sturges M, Colquhoun S: Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Transplant Proc 26: 52-53, 1994
15. Terasaki PI, Yuge J, Cecka JM, Gjertson DW: Cytomegalovirus antibody status and kidney transplantation. Clin Transplant 509-518, 1994
16. Reinke P, Fietze E, Ode-Hakim S, Prosch S, Uppert J, Ewert R, Volk HD: Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344: 1737-1738, 1994
17. Metselaar HJ, Ploeg RJ, van Loon AM, Weiland HT, Rothbarth PH, Paul LC, Brand A, Schaafsma R, Hendriks GFJ, Jeekel J, Weimar W: Prevention of CMV infection by screening for CMV antibodies in renal allograft recipients and their blood and kidney donors. Scand J Infect Dis 20: 135-139, 1988
18. Davis C: The prevention of cytomegalovirus disease in renal transplantation. Am J Kidney Dis 16: 175-188, 1990
19. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL. Levey AS, Strom TB, Carpenter CB. Levey RH, Harmon WE, Zimmerman CE: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 317: 1049-1054, 1987
20. Waid TH, McKeown JW: Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. Transplant Proc 27: 46, 1995
21. Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A: Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J Heart Lung Transplant 14: 659-665, 1995
22. Zamora MR, Fullerton DA, Campbell DN, Leone S, Diercks MJ, Fisher JH, Badesch DB, Grover FL: Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplant Proc 26: 49-51, 1994
23. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rohrer RH, Freeman R, Jenkins R, Lewis WD, O'Rourke E: A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group. Transplant Proc 26: 23-27, 1994
24. Tenschert W, Gonnermann D, Meyer-Moldenhauer WH, Cremaschi L, Huland H: Management of cytomegalovirus infection in high-risk recipients after renal transplantation: Prophylaxis by hyperimmunoglobulins or DHPG treatment? Transplant Proc 25: 3256-3258, 1993
25. Metselaar HJ, Rothbarth PH, Brouwer RML, Wenting GL, Jeekel J, Weimar W: Prevention of cytomegalovirus-related death by passive immunization: A double blind placebo controlled study in kidney transplant recipients treated for rejection. Transplantation 48: 264-266, 1989
26. Steinmuller DR, Novick AC, Streem SB, Graneto D, Swift C: Intravenous immunoglobulin infusions for the prophylaxis of secondary CMV infection. Transplantation 49: 68-70, 1990
27. Wittes JT, Kelly A, Plante KM: Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 28[Suppl 2]: 17-24, 1996
28. Glowacki LS, Smaill FM: Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients: A meta-analysis. Clin Transplant 8: 10-18, 1994
29. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, Rohrer RH, Freeman R, Jenkins R, Lewis WD, Hammer S, O'Rourke E, Grady GF, Fawaz K, Kaplan MM: Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double blind, placebo controlled trial. Ann Intern Med 119: 984-991, 1993
30. Chitwood KK, Heim-Duthoy KL, Ney AL, Kasiske BL: Questionable benefit of prophylactic acyclovir in renal transplant recipients at high risk for CMV disease. Clin Transplant 7: 320-324, 1993
31. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74: 5716-5720, 1977
32. St. Clair MH, Furman PA, Lubbers CM, Elion GB: Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerase by the triphosphate of acyclovir. Antimicrob Agents Chemother 18: 741-745, 1980
33. Cole NH, Balfour HH: In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 6: 255-261, 1987
34. Carrieri G, Jordan ML, Shapiro R, Scantlebury VP, Vivas C, Kusne S, Magnone M, McCauley J, Starzl TE: Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplant Proc 27: 961-963, 1995
35. Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HHJ, Gores PF, Gruessner RW, Matas AJ, Payne WD, Sutherland DER, Najarian JS: A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 57: 876-884, 1994
36. Legendre C, Ducloux D, Ferroni A, Chkoff N, Valette C, Geffrier C, Rouzioux C, Kreis H: Acyclovir in preventing CMV infection in kidney transplant recipients: A case controlled study. Transplant Proc 25: 1431-1433, 1993
37. Balfour HH Jr, Chace BA, Stapelton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381-1387, 1989
38. Wong T, Lavaud S, Toupance O, Carquin J, Wynckel A, Melin JP, Hanrotel C, Chanard J: Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients. Transplant Int 6: 285-289, 1993
39. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R: Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 7: 325-330, 1996
40. Winston DJ, Wirin D, Shaked A, Busuttil RW: Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346: 69-74, 1995
41. Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachcinski R, Irish W, Kisor D, Felsner I, Rinaldo C, Stieber A, Fung J, Ho MA: A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58: 779-785, 1994
42. Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, Williams PA, Johnson BA, Griffith BP: A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 150: 146-152, 1994
43. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T: High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: A randomized trial. Ann Intern Med 120: 375-381, 1994
44. Morales JM, Munoz MA, Campo C, Andres A, Araque A, Alamo C, Praga M, Ortuno T, Hernandez E, Rodicio JL: Renal transplantation in older patients with double therapy with optional change to cyclosporin monotherapy: Long-term results [Abstract]. Transplant Proc 26: 2511-2512, 1994
45. Paya CV, Marin E, Keating M, Dickson R, Porayko M, Wiesner R: Solid organ transplantation: Results and implications of acyclovir use in liver transplants. J Med Virol [Suppl 1]: 123-127, 1993
46. Nevins TE, Dunn DL: Use of ganciclovir for cytomegalovirus infection. J Am Soc Nephrol 2: S270-S273, 1992
47. Shepp DH, Dandliker PS, de Miranda P, Burnette TC, Cederberg DM, Kirk LE, Meyers JD: Activity of 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 103: 368-373, 1985
48. Masur H, Lane HC, Palestine A, Smith PD, Manischewitz J, Stevens G, Fujikawa L, Macher AM, Nussenblatt R, Baird B, Megill M, Wittek A, Quinnan GV, Parrillo JE, Rook AH: Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 104: 41-44, 1986
49. Collaborative DHPG Treatment Study Group: Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 314: 801-805, 1986
50. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial. Ann Intern Med 123: 18-26, 1995
51. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N: Preemptive ganciclovir therapy in cytomegalovirus-sero-positive renal transplants recipients. Arch Surg 130: 1217-1221, 1995
52. Brennan DC, Garlock KA, Singer GG, Schnitzler MA, Lippman BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Shenoy S, Howard TK, Storch GA: Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64: 1843-1846, 1997
53. Conti DJ, Singh TP, Gruber SA, Freed BM, Lempert N: Gancyclovir prophylaxis of cytomegalovirus disease. ASTP Abstract Book 1996, CD-ROM
54. Rondeau E, Bourgeon B, Peraldi MN, Lang P, Buisson C, Schulte KM, Weill B, Sraer JD: Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 8: 858-862, 1993
55. Conti DJ, Freed BM, Gruber SA, Lempert N: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: A trial of ganciclovir vs immunoglobulin. Arch Surg 129: 443-447, 1994
56. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Miillar RC, DuMond C, DeAmond B, Sullivan VA: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326: 1182-1186, 1992
57. MacDonald PS, Keogh AM, Marshman D, Richens D, Harvison A, Kaan AM, Spratt PM: A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 14: 32-38, 1995
58. Aguado JM, Gomez-Sanchez MA, Lumbreras C, Delgado J, Lizasoain M, Otero JR, Rufilanchas JJ, Noriega AR: Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 39: 1643-1645, 1995
59. Valacyclovir. The Medical Letter 38: 3-4, 1996
60. Mendez R, Noriega A, Lowance D: Valaciclovir (VALTREX™) reduces the incidence of CMV disease in CMV-seropositive cadaveric renal allograft recipients [Abstract]. Presented at the 6th International Cytomegalovirus Workshop, March 5-9, 1997
61. Squiilet JP, Mendez R, Lee I: Valaciclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive renal allograft recipients [Abstract]. Presented at the 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997
62. Neumayer HH, Kreis H, Squifflet JP: Efficacy and safety of valaciclovir for suppression of cytomegalovirus disease in recipients of a cadaveric renal allograft [Abstract]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 to October 1, 1997
63. Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C: Viral prophylaxis in hepatic transplantation: Preliminary report of a randomized trial of acyclovir and gancyclovir. Transplant Proc 25: 1935-1937, 1993
64. Brennan DC, Garlock KA, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Miller SB, Shenoy S, Howard TK, Storch GA: Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8: 118-125, 1997
65. van den Berg AP, van Son WJ, Janssen RA, Brons NH, Heyn AA, Scholten-Sampson A, Postma S, van der Giessen M, Tegzess AM, de Leij LH: Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes. J Infect Dis 166: 1228-1235, 1992
66. Gane E, Saliba F, Valdecasas G, O'Grady J, Behrend M, Pescovitz MD, Pruett T, Hockerstedt K, Bröesch C, Mino-Fugarolas G, Houssin D, Davis C, Henry M, Erhard J, Kam I: Efficacy and safety of oral gancyclovir in the prevention of CMV disease in liver transplant recipients: Results of a multicenter, multinational clinical trial. ASTP Abstract Book 1996, CD-ROM
67. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, Robinson CA: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350: 1729-1733, 1997
68. Martin M: Combination protocols for prevention of CMV disease in the high risk transplant patient. Transplant Proc 28[Suppl 2]: 12-13, 1996
69. Tsevat J, Snydman DR, Pauker SG, Durand-Zaleski I, Werner BG, Levey AS: Which renal transplant patients should receive cytomegalovirus immune globulin? Transplantation 52: 259-265, 1991
70. Riera L, Seron D, Castelao AM, Grino JM, Franco E, Bover J, Vigues L, Alsina J, Serrallach N: Renal transplantation in cyclosporin-treated patients over age 50 [Abstract]. Transplant Proc 24: 122-123, 1992
71. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz MD, Martin M, Paya CV: Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61: 1279-1289, 1996
72. Dickinson BI, Gora-Harper ML, McCraney SA, Gosland M: Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Ann Pharmacother 30: 1452-1464, 1996
73. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 24: 458-464, 1997
74. Weir MR, Henry ML, Blackmore M, Smith J, First MR, Irwin B, Shen S, Genemans G, Alexander JW, Corry RJ, Ngheim DD, Ferguson RM, Kittur D, Shield CF, Sommer BG: Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. Transplantation 45: 111-116, 1988
75. Mancilla E, Alberu J, Alessio-Robles L, Elizondo J, Reyes E, Sifuentes-Osornio J, Bordes-Aznar J: Prevalence of clinically overt cytomegalovirus disease in kidney transplant patients. Transplant Proc 24: 1919-1920, 1992
76. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H Jr, Rubin RH: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53: 68-72, 1992
77. Peterson PK, Balfour HH, Marker SC, Fryd DS, Howard RJ, Simmons RL: Cytomegalovirus disease in renal allograft recipients: A prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) 59: 283-300, 1980
78. Grundy JE, Super M, Sweny P, Moorhead J, Lui SF, Berry SF, Fernando ON, Griffiths PD: Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2: 132-135, 1988
79. Chatterjee SN, Jordan GW: Prospective study of the prevalence and symptomatology of cytomegalovirus infection in renal transplant recipients. Transplantation 28: 457-460, 1979
80. Ho M, Suwansirikul S, Dowling JN, Youngblood LA, Armstrong JA: The transplanted kidney as a source of cytomegalovirus infection. N Engl J Med 293: 1109-1112, 1975
81. Cuhadaroglu S, Cohen B, Haberal M: Incidence and prophylaxis of cytomegalovirus infection and disease in seronegative patients receiving kidneys from seropositive donors. Transplant Proc 24: 2626-2627, 1992
82. Conlon PJ Jr, Carmody M, Donohoe J, Spencer S, Smyth E, Walshe JJ: Cytomegalovirus infection as a complication of OKT3 therapy in kidney transplant recipients. Ir J Med Sci 161: 630-632, 1992
83. Greger B, Vallbracht A, Kurth J, Schareck WD, Muller GH, Hopt UT, Bockhorn H: The clinical value of CMV prophylaxis by CMV hyperimmune serum in the kidney transplant patient. Transplant Proc 18: 1387, 1986
84. Fassbinder W, Ernst W, Hanke P, Bechstein PB, Scheuermann EH, Schoeppe W: Cytomegalovirus infection after renal transplant: Effect of prophylactic hyperimmune globulin. Transplant Proc 18: 1393, 1986
85. Kletzrnayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R: Impact of high dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 7: 325-330, 1996
86. Hopt UT, Pfeffer F, Schareck W, Busing M, Ming C: Ganciclovir for prophylaxis of CMV disease after pancreas/kidney transplantation. Transplant Proc 26: 434-435, 1994
87. Singh TP, Gruber SA, Lempert N, Freed B, Conti DJ: Efficacy of cytomegalovirus prophylaxis in renal retransplantation. Transplant Proc 27: 964-965, 1995